Evidence map›Paper›PMID 36173392›Full record

ReviewJournal of natural products2022

Total Heterologous Biosynthesis of Fungal Natural Products in

Yi-Ming Chiang, Tzu-Shyang Lin, Clay C C Wang

Open access · greenAbstract readReview
In one paragraph

Review in Journal of natural products, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Metabolic reprogramming of abscisic acid-producing strainSynthetic and systems biotechnology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Terpenoid balance inScience advances · 2024
    Article
  19. Article
  20. Synthetic Biology Tools for EngineeringJournal of fungi (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Yi-Ming ChiangDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0001-9899-1364
Tzu-Shyang LinDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Clay C C WangDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-2955-7569
University of Southern California · US

Funding

Exploiting interspecies/interkingdom communication for the discovery and development of novel natural products antifungal therapeuticsR21AI127640 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, CLAY CC · 2017 to 2018
$449k
NIAID NIH HHS R21 AI127640
6 · The paper itself

Abstract

Fungal natural products comprise a wide range of bioactive compounds including important drugs and agrochemicals. Intriguingly, bioinformatic analyses of fungal genomes have revealed that fungi have the potential to produce significantly more natural products than what have been discovered so far. It has thus become widely accepted that most biosynthesis pathways of fungal natural products are silent or expressed at very low levels under laboratory cultivation conditions. To tap into this vast chemical reservoir, the reconstitution of entire biosynthetic pathways in genetically tractable fungal hosts (total heterologous biosynthesis) has become increasingly employed in recent years. This review summarizes total heterologous biosynthesis of fungal natural products accomplished before 2020 using

Indexed as

Aspergillus nidulansBiological ProductsBiosynthetic PathwaysGenes, FungalGenome, FungalMultigene FamilyBiological Products

Identifiers

PMID36173392
PMCPMC9621686
OpenAlexW4297965606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.